Intech Biopharm Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

17.51

EPS

—

Div Yield, %

—

Shrs. gr., 5y

7.94%

Rev. gr., 5y

38.49%

Revenues

108m

+170.31%

Net income

-389m

L+5.66%

CFO

-361m

L+34.14%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Profile

Intech Biopharm Corporation is a pharmaceutical company dedicated to the global development and production of generic medications for respiratory conditions. Their portfolio includes innovative drug delivery systems, such as iLEF (inhaled low ethanol formulation), a proprietary metered dose inhaler platform specifically engineered for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Additionally, they offer a dry powder inhaler (DPI) technology, which utilizes blisters and capsules for precise dosage. These therapeutic solutions are marketed under various brand names, including SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011. Established in Taipei, Taiwan, in 2010, the company maintains its headquarters in the city.

URL

http://www.intechbiopharm.com/

IPO date

Jul 15, 2014

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title TWD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title TWD in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT